20920-98-3

Basic information

• Product Name: 6-methoxy-3,4-dihydro-2H-chromen-2-one
• CAS NO: 20920-98-3
• Molecular Formula: C₁₀H₁₀O₃
• Molecular Weight: 178.1846
• Mol File: 20920-98-3.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 319°C at 760 mmHg
• Flash Point: 130.9°C
• Density: 1.205g/cm³
• Vapor Pressure: 0.000349mmHg at 25°C
• Refractive Index: 1.546
• CAS DataBase Reference: 6-methoxy-3,4-dihydro-2H-chromen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methoxy-3,4-dihydro-2H-chromen-2-one(20920-98-3)
• EPA Substance Registry System: 6-methoxy-3,4-dihydro-2H-chromen-2-one(20920-98-3)

Safety Data

• Hazardous Substances Data: 20920-98-3(Hazardous Substances Data)

Usage

General Description

6-methoxy-3,4-dihydro-2H-chromen-2-one, also known as scopoletin, is a naturally occurring compound found in various plant species. It belongs to the class of organic compounds known as coumarins, and is often used for its pharmacological properties, including its anti-inflammatory, antioxidant, and anti-cancer effects. Scopoletin has been studied for its potential to inhibit tumor growth and induce cell death in cancer cells, making it a promising candidate for future cancer therapies. It has also been investigated for its role in cardiovascular health and its ability to protect against oxidative stress. Additionally, scopoletin has been used in traditional medicine for its analgesic and anti-inflammatory properties. Overall, its diverse pharmacological effects make 6-methoxy-3,4-dihydro-2H-chromen-2-one an important compound in the field of natural product research.

Upstream product

• 5111-70-6 5-methoxy-1-indanone 
• 33538-99-7 2-hydroxy-5-methoxycinnamaldehyde 
• 17372-53-1 6-methoxycoumarin 
• 10026-13-8 phosphorus pentachloride 
• 20811-60-3 3-(4-methoxyphenoxy)propanoic acid 
• 71-43-2 benzene 
• 87823-55-0 methoxy-6 diethoxy-2,2 benzopyranne-1 
• 150-76-5 4-methoxy-phenol 
• 140-88-5 ethyl acrylate 

Downstream Products

• 225791-33-3 2-hydroxy-5-methoxybenzenepropanoic acid 
• 736985-86-7 2-hydroxy-6-methoxychroman 
• 1360546-21-9 (E)-ethyl 3-(2-(3-(dibenzylamino)-3-thioxopropyl)-4-methoxyphenyl)acrylate 
• 1360546-31-1 ethyl 2-((1S,2R)-2-(dibenzylcarbamothioyl)-5-methoxy-2,3-dihydro-1H-inden-1-yl)acetate 
• 1323994-13-3 (R(S))-6-methoxy-2-[(p-tolylsulfinyl)methyl]chroman-2-ol 
• 1323994-17-7 C₁₈H₂₀O₄S 
• 1323994-60-0 (2S,R(S))-6-methoxy-2-[(p-tolylsulfinyl)methyl]chroman 
• 1323994-62-2 (2R,R(S))-6-methoxy-2-[(p-tolylsulfinyl)methyl]chroman 
• 33538-88-4 3-(2',5'-dimethoxyphenyl)propanal 
• 33538-81-7 3-(2,5-Dimethoxyphenyl)propanol 
• 33538-76-0 5-Methoxy-2-hydroxyhydrozimtalkohol 
• 20921-09-9 ethyl 3-(2-hydroxy-5-methoxyphenyl)propionate 

Relevant articles and documents

Organocatalyst-Mediated Dynamic Kinetic Enantioselective Acylation of 2-Chromanols

We recently developed a novel chiral catalyst-directed dynamic kinetic diastereoselective acylation of hemiacetals for the synthesis of carbohydrates. In this update, we describe a catalytic method for the dynamic kinetic enantioselective acylation of 2-c

Substd. 2 - (chromane-6-carbonoyloxysilane) and its use as medicine iminothiazole-

PROBLEM TO BE SOLVED: To provide: a compound usable for disorders such as arrhythmia, cardiac failure and cerebral apoplexy caused by disturbance of intracellular calcium homeostasis of sodium-calcium exchanger (NCX), especially sodium-calcium exchanger of subtype 1 (NCX1); production method of the compound; use thereof as a pharmaceutical; and a pharmaceutical composition including the compound.SOLUTION: There is disclosed a substituted 2-(chroman-6-yloxy)-thiazole compound expressed by general formula I.

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals

Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.